{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:31:17Z","timestamp":1793809877725,"version":"4.6.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["422681845"],"award-info":[{"award-number":["422681845"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.pharmthera.2021.107987","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:09:25Z","timestamp":1630494565000},"page":"107987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Mineralocorticoid receptors in pulmonary hypertension and right heart failure: From molecular biology to therapeutic targeting"],"prefix":"10.1016","volume":"231","author":[{"given":"Argen","family":"Mamazhakypov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Lother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107987_bb0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0010","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1096\/fj.201500042","article-title":"Up-regulation of the mammalian target of rapamycin complex 1 subunit raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension","volume":"30","author":"Aghamohammadzadeh","year":"2016","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0015","doi-asserted-by":"crossref","first-page":"H1204","DOI":"10.1152\/ajpheart.00246.2014","article-title":"Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model","volume":"307","author":"Aguero","year":"2014","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0020","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/HYPERTENSIONAHA.119.14330","article-title":"Pulmonary hypertension due to left heart disease: Diagnosis, pathophysiology, and therapy","volume":"75","author":"Al-Omary","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0025","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA\u2013salt\u2013induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejim.2019.02.014","article-title":"Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure - A danish nationwide registry-based study","volume":"63","author":"Andersson","year":"2019","journal-title":"European Journal of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0035","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-16-0661","article-title":"30 Years of the mineralocorticoid receptor: evolution of the mineralocorticoid receptor: Sequence, structure and function","volume":"234","author":"Baker","year":"2017","journal-title":"The Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0040","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0045","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/HYPERTENSIONAHA.115.06172","article-title":"Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure","volume":"66","author":"Barrett Mueller","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/ajh\/hpy158","article-title":"Vascular mineralocorticoid receptor: Evolutionary mediator of wound healing turned harmful by our modern lifestyle","volume":"32","author":"Biwer","year":"2019","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12890-018-0604-x","article-title":"Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension","volume":"18","author":"Boehm","year":"2018","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.201607-1515PP","article-title":"Translating research into improved patient care in pulmonary arterial hypertension","volume":"195","author":"Bonnet","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2013.08.102","article-title":"A cornerstone of heart failure treatment is not effective in experimental right ventricular failure","volume":"169","author":"Borgdorff","year":"2013","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0070","first-page":"22","article-title":"Renal denervation reduces pulmonary vascular remodeling and right ventricular diastolic stiffness in experimental pulmonary hypertension","volume":"2","author":"Bos","year":"2017","journal-title":"JACC: Basic to Translational Science"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0075","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cvr\/cvx145","article-title":"RV pressure overload: From hypertrophy to failure","volume":"113","author":"van der Bruggen","year":"2017","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0080","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/heartjnl-2015-308365","article-title":"Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension","volume":"102","author":"Calvier","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0085","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","article-title":"Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion","volume":"102","author":"Caprio","year":"2008","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0090","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/HJH.0000000000002527","article-title":"A speckle tracking echocardiographic study on right ventricular function in primary aldosteronism","volume":"38","author":"Chen","year":"2020","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0095","doi-asserted-by":"crossref","first-page":"T83","DOI":"10.1530\/JOE-17-0155","article-title":"30 Years of the mineralocorticoid receptor: Mineralocorticoid receptor null mice: Informing cell-type-specific roles","volume":"234","author":"Cole","year":"2017","journal-title":"The Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0105","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/FJC.0b013e31822a78c1","article-title":"Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism","volume":"58","author":"Deshmukh","year":"2011","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.mce.2011.07.019","article-title":"Non-genomic actions of aldosterone: From receptors and signals to membrane targets","volume":"350","author":"Dooley","year":"2012","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: First global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0125","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","article-title":"30 Years of the mineralocorticoid receptor: The role of the mineralocorticoid receptor in the vasculature","volume":"234","author":"DuPont","year":"2017","journal-title":"The Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88942","article-title":"Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging","volume":"1","author":"DuPont","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/cvr\/cvx198","article-title":"Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-kappaB and AP-1 signalling","volume":"114","author":"Elinoff","year":"2018","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0140","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0150","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCRESAHA.117.312380","article-title":"Pannexin 1 channels as an unexpected new target of the anti-hypertensive drug spironolactone","volume":"122","author":"Good","year":"2018","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0155","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.chembiol.2012.04.014","article-title":"Nuclear shuttling precedes dimerization in mineralocorticoid receptor signaling","volume":"19","author":"Grossmann","year":"2012","journal-title":"Chemistry & Biology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11883-013-0320-1","article-title":"Modulation of 11beta-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation","volume":"15","author":"Hadoke","year":"2013","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1165\/rcmb.2012-0354OC","article-title":"Endothelin-converting enzyme-1 gene ablation attenuates pulmonary fibrosis via CGRP-cAMP\/EPAC1 pathway","volume":"48","author":"Hartopo","year":"2013","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0170","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/ATVBAHA.118.311992","article-title":"Transthoracic pulmonary artery denervation for pulmonary arterial hypertension","volume":"39","author":"Huang","year":"2019","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0180","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/HYPERTENSIONAHA.115.06015","article-title":"Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females","volume":"66","author":"Jia","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2009.12.006","article-title":"Role of apoptosis in pulmonary hypertension: From experimental models to clinical trials","volume":"126","author":"Jurasz","year":"2010","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0190","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/HYPERTENSIONAHA.120.16196","article-title":"Eplerenone improves pulmonary vascular remodeling and hypertension by inhibition of the mineralocorticoid receptor in endothelial cells","volume":"78","author":"Kowalski","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0195","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.yjmcc.2010.07.014","article-title":"Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction","volume":"49","author":"Kreymborg","year":"2010","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107987_bb0200","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.chest.2020.09.258","article-title":"Renin-angiotensin-aldosterone system inhibitor use and mortality in pulmonary hypertension: Insights from the veterans affairs CART database","volume":"159","author":"Lahm","year":"2020","journal-title":"Chest."},{"key":"10.1016\/j.pharmthera.2021.107987_bb0205","doi-asserted-by":"crossref","first-page":"105332","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Leopold","year":"2007","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0215","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12872-016-0366-4","article-title":"Pulmonary artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-aldosterone system","volume":"16","author":"Liu","year":"2016","journal-title":"BMC Cardiovascular Disorders"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-019-1131-x","article-title":"Use of precision cut lung slices as a translational model for the study of lung biology","volume":"20","author":"Liu","year":"2019","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0225","doi-asserted-by":"crossref","first-page":"46846","DOI":"10.18632\/oncotarget.15154","article-title":"Effects of renal denervation on monocrotaline induced pulmonary remodeling","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0230","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCRESAHA.120.317424","article-title":"Mineralocorticoid receptors: Master regulators of extracellular matrix remodeling","volume":"127","author":"Lother","year":"2020","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0235","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-18-0494","article-title":"Endothelial cell mineralocorticoid receptors oppose VEGF-induced gene expression and angiogenesis","volume":"240","author":"Lother","year":"2019","journal-title":"The Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0240","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.115.06530","article-title":"Deoxycorticosterone acetate\/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure","volume":"67","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0245","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pharmthera.2016.07.004","article-title":"Pharmacology of heart failure: From basic science to novel therapies","volume":"166","author":"Lother","year":"2016","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0250","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.116.07418","article-title":"Vascular mineralocorticoid receptors: Linking risk factors, hypertension, and heart disease","volume":"68","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-pharmtox-010814-124302","article-title":"Mineralocorticoids in the heart and vasculature: New insights for old hormones","volume":"55","author":"Lother","year":"2015","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0260","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1086\/674770","article-title":"A comprehensive review: The evolution of animal models in pulmonary hypertension research; are we there yet?","volume":"3","author":"Maarman","year":"2013","journal-title":"Pulm Circ"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0265","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1164\/rccm.201203-0411OC","article-title":"Dysregulated renin\u2013angiotensin\u2013aldosterone system contributes to pulmonary arterial hypertension","volume":"186","author":"de Man","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0270","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.202012-4317SO","article-title":"Pulmonary arterial hypertension: Diagnosis, treatment, and novel advances","volume":"203","author":"Maron","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0275","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1161\/CIRCULATIONAHA.114.006980","article-title":"Emerging concepts in the molecular basis of pulmonary arterial hypertension: Part II: Neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension","volume":"131","author":"Maron","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0280","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.113.007690","article-title":"Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis","volume":"130","author":"Maron","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0285","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/eurjhf\/hfs173","article-title":"Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: A pilot study","volume":"15","author":"Maron","year":"2013","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0290","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.healun.2015.10.019","article-title":"Elevated pulmonary arterial and systemic plasma aldosterone levels associate with impaired cardiac reserve capacity during exercise in left ventricular systolic heart failure patients: A pilot study","volume":"35","author":"Maron","year":"2016","journal-title":"The Journal of Heart and Lung Transplantation"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0295","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2013.04.051","article-title":"Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)","volume":"112","author":"Maron","year":"2013","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0300","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0305","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijcard.2017.01.013","article-title":"Essential role of ICAM-1 in aldosterone-induced atherosclerosis","volume":"232","author":"Marzolla","year":"2017","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0310","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0315","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211025240","article-title":"Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension","volume":"11","author":"Menon","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0320","doi-asserted-by":"crossref","first-page":"107387","DOI":"10.1016\/j.pharmthera.2019.06.009","article-title":"The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease","volume":"203","author":"Moss","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0325","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0330","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.2174\/1381612826666200523171137","article-title":"Aldosterone and mineralocorticoid receptor antagonists on pulmonary hypertension and right ventricular failure: A review","volume":"26","author":"Omidkhoda","year":"2020","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0335","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2215\/CJN.05760513","article-title":"Collecting duct principal cell transport processes and their regulation","volume":"10","author":"Pearce","year":"2015","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0340","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0345","article-title":"Differential microRNA-21 and microRNA-221 upregulation in the biventricular failing heart reveals distinct stress responses of right versus left ventricular fibroblasts","volume":"13","author":"Powers","year":"2020","journal-title":"Circulation: Heart Failure"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0350","doi-asserted-by":"crossref","first-page":"L678","DOI":"10.1152\/ajplung.00300.2012","article-title":"Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension","volume":"304","author":"Preston","year":"2013","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0355","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011343","article-title":"Repurposing medications for treatment of pulmonary arterial hypertension: What\u2019s old is new again","volume":"8","author":"Prins","year":"2019","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0360","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0365","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/CIRCULATIONAHA.120.050682","article-title":"MicroRNA-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload","volume":"143","author":"Ramanujam","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0370","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.113.01803","article-title":"Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone\/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure","volume":"63","author":"Rickard","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0375","doi-asserted-by":"crossref","first-page":"T107","DOI":"10.1530\/JOE-16-0659","article-title":"30 Years of the mineralocorticoid receptor: Nongenomic effects via THE mineralocorticoid receptor","volume":"234","author":"Ruhs","year":"2017","journal-title":"The Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0380","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019898030","article-title":"Spironolactone in pulmonary arterial hypertension: Results of a cross-over study","volume":"10","author":"Safdar","year":"2020","journal-title":"Pulmonary Circulation"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0385","doi-asserted-by":"crossref","DOI":"10.4172\/2161-105X.1000295","article-title":"Circulating aldosterone levels and disease severity in pulmonary arterial hypertension","volume":"5","author":"Safdar","year":"2015","journal-title":"Journal of Pulmonary & Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0390","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.healun.2019.12.002","article-title":"Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis","volume":"39","author":"Samokhin","year":"2020","journal-title":"The Journal of Heart and Lung Transplantation"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0395","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap7294","article-title":"NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension","volume":"10","author":"Samokhin","year":"2018","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0400","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1165\/ajrcmb\/4.2.166","article-title":"Potential regulation of inflammation in the lung by local metabolism of hydrocortisone","volume":"4","author":"Schleimer","year":"1991","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107987_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894019868422","article-title":"EXPRESS: Rates of hospitalization associated with the use of aldosterone receptor antagonists in patients with pulmonary arterial hypertension","volume":"9","author":"Corkish","year":"2019","journal-title":"Pulm Circ"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0405","first-page":"22","article-title":"Renal denervation reduces pulmonary vascular remodeling and right ventricular diastolic stiffness in experimental pulmonary hypertension","volume":"2","author":"da Silva Gon\u00e7alves Bos","year":"2017","journal-title":"JACC: Basic to Translational Science"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0410","first-page":"53","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","author":"Simonneau","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0415","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","article-title":"Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure","volume":"297","author":"Stenmark","year":"2009","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0420","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1152\/physrev.00026.2015","article-title":"Primary aldosteronism: Changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney","volume":"96","author":"Stowasser","year":"2016","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0425","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","article-title":"Aldosterone-induced inflammation in the rat heart: Role of oxidative stress","volume":"161","author":"Sun","year":"2002","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0430","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molmed.2016.11.005","article-title":"Targeting vascular remodeling to treat pulmonary arterial hypertension","volume":"23","author":"Thompson","year":"2017","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0435","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0440","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020941494","article-title":"Repurposing of medications for pulmonary arterial hypertension","volume":"10","author":"Toshner","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0445","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41586-020-2922-4","article-title":"A molecular cell atlas of the human lung from single-cell RNA sequencing","volume":"587","author":"Travaglini","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0450","doi-asserted-by":"crossref","first-page":"L508","DOI":"10.1152\/ajplung.00165.2020","article-title":"Glucose-6-phosphate dehydrogenase deficiency contributes to metabolic abnormality and pulmonary hypertension","volume":"320","author":"Varghese","year":"2021","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0455","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: Insights into its molecular and (patho)physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nuclear Receptor Signaling"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0460","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.920678","article-title":"Effect of aldosterone on senescence and proliferation inhibition of endothelial progenitor cells induced by sirtuin 1 (SIRT1) in pulmonary arterial hypertension","volume":"26","author":"Wang","year":"2020","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0465","first-page":"1","article-title":"Aldosterone contributed to pulmonary arterial hypertension development via stimulating aquaporin expression and pulmonary arterial smooth muscle cells proliferation","author":"Wang","year":"2020","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0470","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/hr.2010.16","article-title":"Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension","volume":"33","author":"Yamanaka","year":"2010","journal-title":"Hypertension Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0475","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/CIRCRESAHA.118.313650","article-title":"Medical therapy for heart failure associated with pulmonary hypertension","volume":"124","author":"Zelt","year":"2019","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2021.107987_bb0480","doi-asserted-by":"crossref","first-page":"107576","DOI":"10.1016\/j.pharmthera.2020.107576","article-title":"Pulmonary arterial hypertension specific therapy: The old and the new","volume":"214","author":"Zolty","year":"2020","journal-title":"Pharmacology & Therapeutics"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:22:02Z","timestamp":1759011722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821001893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":96,"alternative-id":["S0163725821001893"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107987","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740766008.793588633","asserted-by":"object"}]},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptors in pulmonary hypertension and right heart failure: From molecular biology to therapeutic targeting","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107987"}}